Latest Period
Q4 2025
Security Snapshot
Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) Institutional Ownership
CUSIP: 64136E102
13F Institutional Holders and Ownership History from Q4 2024 to Q1 2026
Institutions Reporting
21
Shares (Excl. Options)
1,465,999
Price
$3.88
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.00001 par value per share
- Symbol
- NEUP on Nasdaq
- Shares outstanding
- 5,420,049
- Price per share
- $4.78
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 1,465,999
- Total reported value
- $5,687,252
- % of total 13F portfolios
- 0%
- Share change
- +1,270,661
- Value change
- +$4,548,427
- Number of holders
- 21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share is tracked under CUSIP 64136E102.
- 21 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 21 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $5,687,252 to $4,357,025.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 21 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 64136E102?
CUSIP 64136E102 identifies NEUP - Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 64136E102:
Significant Owners of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | $5,365,401 | 1,033,796 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Lynx1 Capital Management LP | 16% | 0% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| Baselake Partners, LP | 4.1% | -59% | $862,110 | 222,222 | 0% | Baselake Partners, LP | 31 Dec 2025 | |
| Shay Capital LLC | 7.3% | $2,035,520 | 171,629 | Shay Capital LLC | 24 Oct 2025 | |||
| Coastlands Capital LP | 5.1% | $1,423,200 | 120,000 | Coastlands Capital LP | 05 Nov 2025 | |||
| Apeiron Investment Group Ltd. | 4.5% | $376,887 | 72,618 | Apeiron Investment Group Ltd. | 24 Jan 2025 |
As of 31 Dec 2025, 21 institutional investors reported holding 1,465,999 shares of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP). This represents 27% of the company’s total 5,420,049 outstanding shares.
Top 24 Institutional Shareholders
The largest institutional shareholders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) together control 27% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 16% | 875,228 | 0.69% | $3,395,885 | |
| Shay Capital LLC | 3.1% | 169,059 | 0.11% | $655,949 | |
| AdvisorShares Investments LLC | 2.5% | 134,194 | +129% | 0.09% | $520,673 |
| DIADEMA PARTNERS LP | 0.92% | 50,000 | +133% | 0.12% | $194,000 |
| Ikarian Capital, LLC | 0.88% | 47,443 | 0.02% | $184,079 | |
| ADAR1 Capital Management, LLC | 0.55% | 30,000 | 0.01% | $116,400 | |
| FNY Investment Advisers, LLC | 0.49% | 26,500 | 0.03% | $102,000 | |
| VANGUARD GROUP INC | 0.39% | 20,950 | 0% | 0% | $81,286 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.32% | 17,303 | +33% | 0% | $67,135 |
| JANE STREET GROUP, LLC | 0.31% | 16,597 | +5.9% | 0% | $64,396 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.27% | 14,750 | 0% | $57,230 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.26% | 14,000 | 0% | $54,320 | |
| Persistent Asset Partners Ltd | 0.25% | 13,403 | +173% | 0.02% | $52,004 |
| XTX Topco Ltd | 0.22% | 12,008 | 0% | $46,591 | |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.21% | 11,207 | 0% | $43,480 | |
| Merck & Co., Inc. | 0.18% | 10,027 | 0% | 0.01% | $38,905 |
| UBS Group AG | 0.03% | 1,652 | -24% | 0% | $6,409 |
| Tower Research Capital LLC (TRC) | 0.03% | 1,400 | +241% | 0% | $5,432 |
| RHUMBLINE ADVISERS | 0% | 202 | +512% | 0% | $783 |
| MORGAN STANLEY | 0% | 58 | +729% | 0% | $225 |
| BANK OF AMERICA CORP /DE/ | 0% | 18 | +5.9% | 0% | $70 |
| MILLENNIUM MANAGEMENT LLC | 0% | 0 | -100% | $0 | |
| Prosperity Wealth Management, Inc. | 0% | 0 | -100% | $0 | |
| FMR LLC | 0% | 0 | -100% | $0 |
Institutional Holders of Neuphoria Therapeutics Inc. - Common Stock, $0.00001 par value per share (NEUP) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,070,733 | $4,357,025 | +$89,344 | $4.07 | 5 |
| 2025 Q4 | 1,465,999 | $5,687,252 | +$4,548,427 | $3.88 | 21 |
| 2025 Q3 | 195,338 | $2,303,036 | +$535,083 | $11.79 | 15 |
| 2025 Q2 | 177,963 | $1,263,538 | +$105,431 | $7.10 | 9 |
| 2025 Q1 | 163,114 | $935,356 | +$529,238 | $5.76 | 7 |
| 2024 Q4 | 79,719 | $273,435 | +$239,042 | $3.43 | 7 |